In DLBCL, AML, and solid tumors (e.g., in lung and brain), the selective KDM6B inhibitor (GSK-J4) reduces tumor cell survival and enhances chemotherapy responses, suggesting the therapeutic potential of GSK-J4 in the treatment of various types of cancer [37,42]. This evidence concerns the gene KDM6B and diffuse large B-cell lymphoma.